SCS Capital Management LLC Makes New $690,000 Investment in Zoetis Inc. $ZTS

Key Points

• SCS Capital Management LLC acquired 4,193 shares of Zoetis Inc., valued at approximately $690,000, during the first quarter, adding to the increasing institutional interest in the company.
• Zoetis reported earnings of $1.76 per share, exceeding analyst estimates, with revenues reaching $2.46 billion, indicating a 4.2% year-over-year growth.
• Wall Street analysts have a consensus rating of "Moderate Buy" for Zoetis, with target prices generally ranging between $155.00 and $215.00.

SCS Capital Management LLC purchased a new position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 4,193 shares of the company's stock, valued at approximately $690,000.

A number of other hedge funds also recently bought and sold shares of ZTS. 1248 Management LLC purchased a new position in shares of Zoetis in the first quarter valued at approximately $27,000. Saudi Central Bank purchased a new position in shares of Zoetis in the first quarter valued at approximately $29,000. Cornerstone Planning Group LLC lifted its position in shares of Zoetis by 79.3% in the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock valued at $30,000 after acquiring an additional 88 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. increased its holdings in shares of Zoetis by 87.6% in the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company's stock valued at $42,000 after purchasing an additional 120 shares during the last quarter. Finally, Sound Income Strategies LLC increased its holdings in shares of Zoetis by 141.4% in the first quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock valued at $46,000 after purchasing an additional 164 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company's stock.

Zoetis Stock Down 1.5%

NYSE ZTS traded down $2.28 during trading on Friday, reaching $148.33. 3,111,229 shares of the company's stock were exchanged, compared to its average volume of 2,278,915. Zoetis Inc. has a 1 year low of $139.70 and a 1 year high of $200.33. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. The stock has a market cap of $65.74 billion, a P/E ratio of 25.53, a price-to-earnings-growth ratio of 2.42 and a beta of 0.89. The company has a 50 day moving average price of $152.32 and a two-hundred day moving average price of $157.31.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating the consensus estimate of $1.62 by $0.14. The firm had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm's revenue was up 4.2% compared to the same quarter last year. During the same period in the prior year, the business earned $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities research analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently commented on ZTS shares. Piper Sandler increased their price target on Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a report on Monday, August 11th. Leerink Partnrs cut Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Argus reissued a "buy" rating and set a $190.00 target price on shares of Zoetis in a research note on Tuesday. Stifel Nicolaus cut Zoetis from a "buy" rating to a "hold" rating and cut their target price for the stock from $165.00 to $160.00 in a research note on Wednesday, June 18th. Finally, Leerink Partners cut Zoetis from an "outperform" rating to a "market perform" rating and cut their target price for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Five analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $200.88.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.